Blockbuster weight loss jabs ‘significantly lower' the risk of dementia
Researchers found that semaglutide - the active ingredient in Ozempic and Wegovy - could "significantly" slash the risk of the brain-robbing disease in people with type 2 diabetes.
Study leader Professor Rong Xu said: "There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among a high risk population."
Semaglutide, part of a group of drugs called GLP-1 agonists, was originally invented to treat type 2 diabetes.
But trials found it could also cause major weight loss - about 10 to 15 per cent of body weight over 18 months.
It triggers fullness hormones in the gut to prevent hunger and over-eating.
Semaglutide has already been found to lower the risk of heart disease, bowel cancer and fertility issues.
But researchers at Case Western Reserve School of Medicine in Cleveland Ohio, United States, now have evidence it could play a key role in preventing dementia.
The syndrome occurs when brain cells are damaged and their connections stop working properly.
That damage, which worsens over time, impacts memory, thinking and reasoning.
It can be caused by various conditions and events, including obesity diabetes, cardiovascular diseases, traumatic brain injury and stroke.
Previous research has indicated that 45 per cent of dementia cases could be prevented by addressing these " modifiable risk factors".
Feeling Full Naturally: Top 5 Foods That Act Like Weight Loss Jabs
The new study, published in the Journal of Alzheimer's Disease, analysed the electronic records of nearly 1.7million American patients with type 2 diabetes over three years.
Patients taking semaglutide had a "significantly lower" risk of developing Alzheimer's disease-related dementia compared to those on seven other antidiabetic medications.
This included other types of GLP-1R-targeting drugs.
The results were more "profound" in women and older adults.
Prof Xu said the findings support the idea that semaglutide could prevent dementia.
But she cautioned that more research is needed.
"Our results indicate that research into semaglutide's use for dementia prevention will need to be further investigated through randomised clinical trials," Prof Xu added.
Are you eligible for weight loss jabs on the NHS?
By Sam Blanchard, Health Correspondent
THEY are arguably the biggest medical breakthrough of recent times.
And now, so-called ' fat jabs ' are available to many more Brits on the NHS.
In what marks the dawn of a new era, GPs have begun prescribing the weight loss jab Mounjaro in the first anti- obesity rollout of its kind.
More than three million people are thought to be eligible for tirzepatide - the active drug in Mounjaro - the strongest jab on the market.
Health chiefs hope it will turn the tide on England's obesity crisis which has seen rates double since the 1990s.
Injections including Ozempic and Wegovy have previously only been available for type 2 diabetes or through specialist slimming clinics.
Family doctors will now be encouraged to prescribe them in a bid to get more people on the meds.
Experts hope widespread use will slash work sick days and boost the economy, while reducing rates of cancer, heart disease and dementia.
But demand for the drugs is already huge and NHS clinics cannot dish them out fast enough.
Who is eligible in the new rollout?
The new rollout allows GPs to prescribe tirzepatide for weight loss, starting with those patients whose weight places them at greatest health risk.
Top of the list will be those with a body mass index (BMI) of 40 or higher (or 37.5 if from a minority ethnic background) and four weight-related health conditions.
A BMI of 40 is roughly equal to weighing 16st (102kg) for an average height 5'3' woman, or 19st 6lbs (123kg) for an average 5'9' man.
Weight-related conditions include high cholesterol, high blood pressure, prediabetes, type 2 diabetes, obstructive sleep apnoea and heart disease.
Patients will likely be expected to have tried diet and exercise first before being offered a jab.
Many are likely to miss out, as some 13.5million adults in England are obese but only 3.4million are estimated to be eligible in the rollout.
Professor Kamila Hawthorne, chair of the Royal College of GPs, said: 'Currently only patients who meet certain criteria - those who could benefit most - are eligible to be prescribed weight loss drugs on the NHS, and GPs will also need to follow local guidelines when prescribing.
'If your practice advises you that they won't be able to provide weight loss medication, these will likely be the reasons why.
'We appreciate the idea of weight loss medication is an attractive prospect to many patients - and they do have a lot of potential benefits for patients and may be a valuable tool as we try to tackle obesity at a national level – but it's important these medications aren't seen as a silver bullet.
'Weight loss drugs do not come without risk, they can cause side effects which range in seriousness, and they won't be suitable for everyone.
'It's important we don't lose sight of the role lifestyle factors play in achieving a healthy weight.
'The roll out of weight loss medications as a treatment for obesity must not come at the expense of other weight loss services.'
If you are eligible but your GP denies you a prescription, you may be able to ask for a referral to specialist weight management services.
Known as tier 2 and tier 3 weight management services, they may prescribe the jabs after other weight loss attempts.
Many people are expected to find it easier to go private, with the injections widely available from high street pharmacies like Boots, Superdrug, and even Asda.
There are also numerous online pharmacies offering the drugs.
Buying the drugs online might seem like the faster fix – but buyer beware.
Slimming success stories are everywhere but so, too, are tales of horror.
Many patients have been duped by dodgy sellers, suffered severe side effects or even died after taking jabs they bought online.
Bargain prices, easy tick-box applications, or prescriptions with no follow-up, should all be red flags to online shoppers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
26 minutes ago
- The Guardian
Monarch butterflies' mass die-off in 2024 caused by pesticide exposure
A 2024 mass monarch butterfly die-off in California was probably caused by pesticide exposure, new peer-reviewed research finds, adding difficult-to-obtain evidence to the theory that pesticides are partly behind dramatic declines in monarchs' numbers in recent decades. Researchers discovered hundreds of butterflies that had died or were dying in January 2024 near an overwintering site, where insects spend winter months. The butterflies were found twitching or dead in piles, which are common signs of neurotoxic pesticide poisoning, researchers wrote. Testing of 10 of the insects revealed an average of seven pesticides in each, and at levels that researchers suspect were lethal. Proving that pesticides kill butterflies in the wild is a challenge because it is difficult to find and test them soon after they die. Though the sample size is limited, the authors wrote, the findings provide 'meaningful insight' into the die-off and broader population decline. 'The incident gave us a rare opportunity to directly document pesticide exposure and its impacts on monarchs in the real world,' said Staci Cibotti, the study's lead author, and an entomologist and pesticide program specialist with the Xerces Society for Invertebrate Conservation. She added: 'Even though laboratory studies and population models have shown that pesticides are harmful to monarchs, it can be difficult to capture the impacts of pesticides in the field on wild populations. This study helps to fill that gap.' As much as 90% of the monarch butterfly population in some US regions has been wiped out in recent decades, and evidence has pointed to pesticides, climate crisis and habitat loss as the drivers. The butterflies were found adjacent to the Pacific Grove Monarch Sanctuary, one of about 400 wintering sites along California's coast that are crucial points in the monarchs' migratory and reproductive cycles. Xerces counted about 6,600 butterflies overwintering at Pacific Grove in November 2023. Though an investigation by a state agricultural official did not determine a source of the die-off, pesticide residues on crops, lawns and ornamental flowers are a poisoning risk for monarch larvae, and for adults eating nectar. Pesticide run off in shallow water sources near where high numbers of butterflies collectively drink present a risk for the type of mass die-off at Pacific Grove. All the butterflies showed high levels of the same three pyrethroids, a pesticide class widely used in California on agricultural and residential land. The residential applications are not reported, and Cibotti said the presence of the same types of pyrethroids in all the samples points to a nearby residential exposure as the source. Some of the pyrethroid levels found in the monarchs are known to be lethal, and researchers suspect the combined levels of multiple pesticides also probably contributed. Combinations of pesticides can have a synergistic effect that makes them even more toxic. The solution, Cibotti said, is less pesticides. 'These clustering events occur during especially sensitive phases of the migratory cycle, so reducing pesticide exposure during these times is essential not only to prevent immediate losses, but also to improve the population's chances of rebounding the following spring and support its long-term recovery,' Cibotti said.
Daily Mail
40 minutes ago
- Daily Mail
Trump demands UK pharmaceutical giants to lower drug costs sparking fears NHS could pay the price if they refuse
Donald Trump has demanded UK pharmaceutical giants lower prices for America and suggested charging others to make up the difference. He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug prices', sparking fears the NHS will end up paying more. Mr Trump suggested he would use tariffs to push through higher prices if countries resisted. In May Mr Trump signed an executive order demanding drugmakers cut US medicine prices to match those abroad. Yesterday in a letter to 17 pharma companies he said he expected them to deliver on measures by September 29. He asked them to apply 'most favoured nation' pricing to Medicaid, the US health programme for people on low incomes. Mr Trump also asked drugmakers to offer new medicines at the same price in the US as in other developed countries. He said: 'Our citizens pay massively higher prices than other nations pay for the same exact pill... subsidizing socialism aboard [abroad].' British pharma companies AstraZeneca and GSK were among the recipients. Others included Eli Lilly, Johnson & Johnson, Pfizer and Sanofi. The UK Government said it would 'continue to work closely with the US to get the best deal for our pharma industry and deliver mutual benefits for both our countries'.
Daily Mail
40 minutes ago
- Daily Mail
Heston Blumenthal reveals he's taking weight-loss drug Wegovy and shares fears that slimming jabs could pose a threat to the food industry
Heston Blumenthal has revealed he's taking the weight-loss drug Wegovy. The celebrity chef, 59, told how he's been taking the slimming aid to help combat the effects of his bipolar medication, having been diagnosed with type 1 bipolar in 2023. Heston also expressed his fears that the rise in popularity of weight loss jabs could pose a threat to the food industry. Speaking to Times Radio, Heston explained: 'I've put on so much weight, but it's starting to come off now', before adding that his use of the drug is a 'paradox' given the fact he's a restaurateur. The TV personality remarked how he'd lost 'eight kilos' on Wegovy so far, however, he has also dealt with side effects including brain fog, slurred speech and problems with balance. The drugs contain semaglutide, an amino acid, which suppresses appetite by mimicking a hormone telling the brain you are full up. In a new interview, the celebrity chef, 59, told how he's been taking the slimming aid to help combat the effects of his bipolar medication, having been diagnosed with type 1 bipolar back in 2023 [Boxes of Wegovy pictured] Heston issued a warning to the food industry, remarking how the continued use of the popular slimming jabs could have a detrimental affect on it. He explained: 'Wegovy, Ozempic, Mounjaro – you still enjoy food, but it stops appetite, so what's going to happen is people are going to want smaller portions.' Heston added that things were 'going to get much worse in the next six months' for restaurants, before expressing that supermarkets would also be affected. However, the food writer noted that he's 'formulating a plan' in a bid to help the food industry. Elsewhere, last month, Heston revealed he 'had thought about different ways of ending [his life]' before eventually receiving treatment for bipolar disorder. The London-born celebrity chef, who holds a total of seven Michelin stars across his restaurants, was diagnosed with type 1 bipolar after being sectioned - on the insistence of his wife, French entrepreneur Melanie Ceysson - in November 2023. Bipolar disorder is a brain disorder which causes unusual and often sudden changes in mood and energy levels. He spent two weeks heavily medicated in a psychiatric hospital and a further six weeks in a clinic, where he continued with intensive treatment and practised walking meditation. Yet, four years previously, he had already hit rock bottom and was contemplating the method he would use to take his own life. Looking back to filming the cookery show Crazy Delicious in 2019, Heston told The Times: 'I remember lying on the sofa the night before I was due to go to do the show - I didn't want to do it, because of the condition I was in - and I had thought about different ways of finishing [my life]. 'I went through a list: knife? No, can't do that. Gun? Don't have one. Rope? I don't think I could do that; wouldn't know how. It would probably slip off or whatever. 'And there was no train station anywhere near to jump in front of a train.' The father-of-four, whose first eatery, The Fat Duck, was named the best restaurant in the world in 2005, added that he didn't perceive that he was in a depressive state - even when he 'was talking about suicide or death'. He told the publication: 'I must have been in a mixed state [a period of rapid highs and lows], because I was excited about planning my funeral, planning my wake. What music I wanted, who I wanted there - I got quite excited about that.'
